Moya G, Rivera P, Dittenhafer-Reed K
Int J Mol Sci. 2021; 22(13).
PMID: 34209978
PMC: 8268735.
DOI: 10.3390/ijms22137030.
Shi C, Zheng Z, Wang Q, Wang C, Zhang D, Zhang M
PLoS One. 2016; 11(6):e0155758.
PMID: 27299523
PMC: 4907455.
DOI: 10.1371/journal.pone.0155758.
Khanam Irin A, Tom Kodamullil A, Gundel M, Hofmann-Apitius M
J Immunol Res. 2015; 2015:737168.
PMID: 26636108
PMC: 4655260.
DOI: 10.1155/2015/737168.
Boon J, Dusonchet J, Trengrove C, Wolozin B
Front Mol Neurosci. 2014; 7:64.
PMID: 25071441
PMC: 4087324.
DOI: 10.3389/fnmol.2014.00064.
Roy B, Jackson G
Hum Mol Genet. 2014; 23(11):3008-23.
PMID: 24430504
PMC: 4014195.
DOI: 10.1093/hmg/ddu011.
The pallidopyramidal syndromes: nosology, aetiology and pathogenesis.
Kara E, Hardy J, Houlden H
Curr Opin Neurol. 2013; 26(4):381-94.
PMID: 23817214
PMC: 4196641.
DOI: 10.1097/WCO.0b013e3283632e83.
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G
Neurobiol Aging. 2013; 34(12):2889.e5-9.
PMID: 23664753
PMC: 3906605.
DOI: 10.1016/j.neurobiolaging.2013.04.011.
Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.
Yan M, Wang X, Zhu X
Free Radic Biol Med. 2012; 62:90-101.
PMID: 23200807
PMC: 3744189.
DOI: 10.1016/j.freeradbiomed.2012.11.014.
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
Guerreiro P, Huang Y, Gysbers A, Cheng D, Gai W, Outeiro T
J Mol Med (Berl). 2012; 91(4):513-22.
PMID: 23183827
PMC: 3611031.
DOI: 10.1007/s00109-012-0984-y.
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S, Liu M
Future Med Chem. 2012; 4(13):1701-13.
PMID: 22924508
PMC: 3569718.
DOI: 10.4155/fmc.12.110.
Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.
Di Domenico F, Sultana R, Ferree A, Smith K, Barone E, Perluigi M
Antioxid Redox Signal. 2012; 17(11):1490-506.
PMID: 22315971
PMC: 3448940.
DOI: 10.1089/ars.2011.4312.
Tau acts as an independent genetic risk factor in pathologically proven PD.
Charlesworth G, Gandhi S, Bras J, Barker R, Burn D, Chinnery P
Neurobiol Aging. 2012; 33(4):838.e7-11.
PMID: 22221882
PMC: 3629571.
DOI: 10.1016/j.neurobiolaging.2011.11.001.
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease.
Martins M, Rosa A, Guedes L, Fonseca B, Gotovac K, Violante S
PLoS One. 2011; 6(10):e25443.
PMID: 22003392
PMC: 3189215.
DOI: 10.1371/journal.pone.0025443.
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
Yue Z, Lachenmayer M
Mov Disord. 2011; 26(8):1386-97.
PMID: 21538530
PMC: 3150637.
DOI: 10.1002/mds.23737.
Cancer and neurodegeneration: between the devil and the deep blue sea.
Plun-Favreau H, Lewis P, Hardy J, Martins L, Wood N
PLoS Genet. 2011; 6(12):e1001257.
PMID: 21203498
PMC: 3009676.
DOI: 10.1371/journal.pgen.1001257.
Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.
Wider C, Dickson D, Wszolek Z
Neurodegener Dis. 2010; 7(1-3):175-9.
PMID: 20197701
PMC: 2859237.
DOI: 10.1159/000289232.
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.
Edwards T, Scott W, Almonte C, Burt A, Powell E, Beecham G
Ann Hum Genet. 2010; 74(2):97-109.
PMID: 20070850
PMC: 2853717.
DOI: 10.1111/j.1469-1809.2009.00560.x.
LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.
Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N
Neurogenetics. 2009; 11(1):121-5.
PMID: 19458969
DOI: 10.1007/s10048-009-0198-9.
